Pre-Open Stock Movers 09/27: (GI) (KITE) (INFI) Higher; (NAT) (SXL) (RICE) Lower (more...)

September 27, 2016 9:08 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Today's Pre-Open Stock Movers

EndoChoice Holdings, Inc. (NYSE: GI) 88.9% HIGHER; Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire EndoChoice.

Kite Pharma, Inc., (Nasdaq: KITE) 12.5% HIGHER; announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 met the primary endpoint of objective response rate (ORR), p<0.0001, with ORR of 76 percent, including 47 percent complete remissions (CR).

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) 11.1% HIGHER; announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. Preliminary Phase 1 results from nine patients with advanced solid tumors show that the safety, pharmacokinetics and pharmacodynamics of IPI-549 monotherapy treatment appear favorable. Additionally, new preclinical data demonstrate that IPI-549 can reverse tumor resistance to checkpoint inhibitors, providing additional rationale for the planned evaluation of IPI-549 in combination with a checkpoint inhibitor in the ongoing Phase 1 study. These data are being presented in a poster session at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival taking place in New York City.

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) 8.9% HIGHER; announced that it has today presented new preclinical data demonstrating in vivoefficacy of its lead 4-1BB (CD137)-based bispecific cancer immunotherapeutic drug candidate, PRS-343, at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference - Translating Science into Survival, taking place in New York City.

SYNNEX Corp. (NYSE: SNX) 7% HIGHER; reported Q3 EPS of $1.73, $0.17 better than the analyst estimate of $1.56. Revenue for the quarter came in at $3.67 billion versus the consensus estimate of $3.49 billion. GUIDANCE: SYNNEX Corp. sees Q4 2016 EPS of $2.06-$2.11, versus the consensus of $1.93. SYNNEX Corp. sees Q4 2016 revenue of $3.83-.93 billion, versus the consensus of $3.77 billion.

Nordic American Tankers Limited (NYSE: NAT) 6.9% LOWER; announced the pricing of its previously announced underwritten public offering pursuant to the Company's effective shelf registration statement. The Company agreed to sell 11,000,000 common shares at a public offering price of $10.00 per share.

ProNAi Therapeutics, Inc. (Nasdaq: DNAI) 6.4% HIGHER; announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1). PNT737 is being investigated in two recently initiated Phase 1 clinical trials, currently sponsored and managed by the Cancer Research UK Centre for Drug Development, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.

Sunoco Logistics Partners L.P. (NYSE: SXL) 5.7% LOWER; Sunoco Logistics Partners L.P. and the Vitol Group today announced the Partnerships strategic acquisition of Vitols Permian Basin crude oil system. The Partnership entered into an agreement with Vitol Inc. to purchase an integrated crude oil business in West Texas for approximately $760 million plus working capital. In addition, Sunoco Logistics Partners L.P. announced that it has commenced an underwritten public offering of 21,000,000 common units.

Array Biopharma (NASDAQ: ARRY) 5.1% HIGHER; adds to Monday's 81% intra-day gains following positive trial data.

Juno Therapeutics Inc (NASDAQ: JUNO) 5.4% HIGHER; gains on KITE news.

Rice Energy Inc. (NYSE: RICE) 4.2% LOWER; announced it has entered into a purchase and sale agreement to acquire Vantage Energy, LLC and Vantage Energy II, LLC for approximately $2.7 billion, including the assumption of debt. In connection with the acquisition, Rice Midstream Partners LP (NYSE: RMP) will purchase the acquired midstream assets from Rice Energy for $600 million. In addition, Rice Energy announced the commencement of an underwritten public offering of 40,000,000 shares of its common stock.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Crude Oil, S3, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers

Add Your Comment